Table 2.

Clinical trials for liver fibrosis.

Drug	Study phase	Status	Clinical trials identifier
Simtuzumab	II	Terminated	NCT01672853 NCT01672866 NCT01452308
GS-4997 alone or in combination with simtuzumab	II	Completed	NCT02466516
Peginterferon α-2b and glycyrrhizin in interferon	III	Terminated	NCT00686881
Peginterferon α-2b and ribavirin	III	Completed	NCT00323804
Cyclosporine A and tacrolimus	IV	Terminated	NCT00260208
Entecavir and peg-interferon	IV	Completed	NCT01938781
Entecavir and anluohuaxian	–	Recruiting	NCT03568578
Entecavir + Fuzheng Huayu + TCM granule	IV	Recruiting	NCT02241616
Candesartan and ramipril	III	Recruiting	NCT03770936
Candesartan	I, II	Completed	NCT00990639
Pirfenidone	II	Recruiting	NCT04099407
Oltipraz	II	Completed	NCT00956098
Methotrexate	–	Completed	NCT00673101
Raltegravir and ritonavir-boosted protease inhibitor	II	Completed	NCT01231685
Losartan	IV	Completed	NCT00298714
GB1211	I	Recruiting	NCT03809052
BLD-2660	I	Recruiting	NCT03559166
Spirulina	–	Completed	NCT02744105
GR-MD-02	II	Completed	NCT02421094
ND-L02-s0201 injection	I	Completed	NCT02227459
Selonsertib	III	Completed	NCT03053050
MGL-3196	III	Recruiting	NCT03900429
Emricasan	II	Completed	NCT02686762
Silymarin, ursodeoxycholic acid, and colchicine	–	Completed	NCT03659058
Silybin + vitamin E + phospholipids complex	III	Completed	NCT01935817
Tacrolimus, antithymocyte globulins + mycophenolate mofetil, tacrolimus + antithymocyte globulins	IV	Completed	NCT00538265
Irbesartan	III	Completed	NCT00265642
Synbiotic	II, III	Completed	NCT01791959
Tropifexor and cenicriviroc	II	Recruiting	NCT03517540
Cenicriviroc	III	Recruiting	NCT03028740
Pentoxyphilline and tocopherol	III	Terminated	NCT00119119
Resveratrol	II, III	Completed	NCT02030977

−Not applicable.